Rethinking Clinical Trials

SEPTEMBER 13, 2023

The secondary outcomes were severe complications between induction and 2 minutes after intubation, such as severe hypoxemia, severe hypotension, new or increased vasopressor administration, cardiac arrest, or death. Learn more Read more in the New England Journal of Medicine. in the direct laryngoscope group.

Trials 141

Trials Clinical Trials Clinical Trials Medicine 141

The Pharma Data

OCTOBER 21, 2020

21, 2020 — A combination of two “targeted” therapies can beat back a rare form of blood cancer — without the toxic effects of chemotherapy, a new study has found. 22 in the New England Journal of Medicine , could lead to an effective — and chemo-free — treatment for the cancer.

Drugs 52

Drugs Genetics Trials Research 52

The Pharma Data

OCTOBER 21, 2020

21, 2020 — A combination of two “targeted” therapies can beat back a rare form of blood cancer — without the toxic effects of chemotherapy, a new study has found. 22 in the New England Journal of Medicine , could lead to an effective — and chemo-free — treatment for the cancer.

Drugs 52

Drugs Genetics Trials Research 52

XTalks

FEBRUARY 11, 2021

Today, new next-generation sequencing technologies allow for the sequencing of complex genomes within just a day or two. This has ushered in a new era of genomics that is fostering rapid, detailed and personalized insights into human genetics. Born in Notting Hill, London, England to a prosperous British Jewish family on July 25, 1920.

Genetics 119

Genetics DNA Genome Genomics 119

The Pharma Data

MAY 4, 2021

NEW YORK–(BUSINESS WIRE)– Pfizer Inc. Internal Medicine. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Lorbrena, expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

Vaccination 40

Vaccination Vaccine Production Sales 40